Sign in

COCH on Nasdaq

Envoy Medical, Inc.

Envoy Medical, Inc. is an orthopedic company, listed on Nasdaq (COCH).1 It is headquartered in White Bear Lake, Minnesota.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Lifeward Ltd., Cuprina Holdings (Cayman) LTD or United Health Products, Inc., or pick any stock.

  • TickerCOCH on Nasdaq1
  • IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
  • HeadquartersWhite Bear Lake, Minnesota1
  • Business address4875 White Bear Parkway, White Bear Lake, Mn 551102
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

FI-AMEI and we continue to work towards having the Esteem FI-AMEI properly classified as a Fully Implanted Active Middle Ear Implant.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-9240.7%Operating margin4
-9857.3%Net margin4
7.1%Revenue growth, 20254
-$18.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue7¢$874.0K
  • Research and development93¢$12.5M

Out of $241.0K in revenue.4 The company lost money this year.

Financial statements

Revenue564$241.0K in 2025+2% since 2022
0$100.0K$200.0K$300.0K$400.0K2022: $237.0K$237.0K20222023: $316.0K$316.0K2023+33%2024: $225.0K$225.0K2024−29%2025: $241.0K$241.0K2025+7%
Operating income7564-$22.3M in 2025+328% since 2021
-$30.0M-$20.0M-$10.0M02021: -$5.2M-$5.2M20212022: -$8.7M-$8.7M2022+67%2023: -$18.4M-$18.4M2023+111%2024: -$19.3M-$19.3M2024+5%2025: -$22.3M-$22.3M2025+16%
Net income7564-$23.8M in 2025+9341% since 2021
-$30.0M-$20.0M-$10.0M02021: -$251.6K-$251.6K20212022: -$15.9M-$15.9M2022+6228%2023: -$29.9M-$29.9M2023+88%2024: -$20.8M-$20.8M2024−31%2025: -$23.8M-$23.8M2025+14%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Net revenues$241.0K$225.0K
Cost of goods sold$874.0K$742.0K
Research and development$12.5M$10.2M
Sales and marketing$1.2M$1.7M
General and administrative$7.9M$6.8M
Total costs and operating expenses$22.5M$19.5M
Operating loss-$22.3M-$19.3M
Change in fair value of forward purchase agreement put option liability$103.0K
Change in fair value of forward purchase agreement warrant liability$534.0K$411.0K
Change in fair value of forward purchase agreement warrant liability due to extension-$24.0K-$881.0K
Loss on offering and change in fair value of private warrant liability-$494.0K
Change in fair value of publicly traded warrant liability$111.0K-$330.0K
Interest expense, related party-$1.6M-$816.0K
Other expense, net-$23.0K-$26.0K
Total other income (expense), net-$1.5M-$1.5M
Net loss-$23.8M-$20.8M
Induced conversion of Series A Preferred Stock into Class A Common Stock-$1.2M
Deemed dividend on waiver of restriction on Class A Common Stock-$495.0K
Cumulative preferred dividends-$4.9M-$5.5M
Net loss attributable to common stockholders, basic-$28.7M-$28.0M
Net loss attributable to common stockholders, diluted-$28.7M-$28.0M
Net loss per share attributable to common stockholders, basic (in Dollars per share)-$1.23-$1.49
Net loss per share attributable to common stockholders, diluted (in Dollars per share)-$1.23-$1.49
Weighted-average Class A Common Stock outstanding, basic (in Shares)23.3M shares18.8M shares
Weighted-average Class A Common Stock outstanding, diluted (in Shares)23.3M shares18.8M shares
Foreign currency translation adjustment$3.0K-$5.0K
Other comprehensive income (loss)$3.0K-$5.0K
Comprehensive loss-$23.8M-$20.8M

Compare Envoy Medical, Inc. with another company

Corporate structure

Envoy Medical, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Envoy Medical, Inc.

  • Alta Partners LLC Filed SCHEDULE 13G/A on Envoy Medical, Inc., latest Sep 14, 2026 (2 filings since Aug 21, 2025)
  • Nantahala Capital Management, LLC Filed SCHEDULE 13G on Envoy Medical, Inc., latest May 15, 2026
  • Bleichroeder LP Filed SCHEDULE 13G on Envoy Medical, Inc., latest May 14, 2026
  • Ayrton Capital LLC Filed SCHEDULE 13G/A on Envoy Medical, Inc., latest May 11, 2026 (2 filings since Feb 11, 2026)
  • Glen A. Taylor Filed SCHEDULE 13D/A on Envoy Medical, Inc., latest Feb 17, 2026 (2 filings since Dec 8, 2025)
  • ARISTEIA CAPITAL, L.L.C. Filed SCHEDULE 13G/A on Envoy Medical, Inc., latest May 15, 2025 (5 filings since Feb 14, 2022)
  • Walleye Capital LLC Filed SCHEDULE 13G/A on Envoy Medical, Inc., latest Feb 6, 2025 (2 filings since Nov 13, 2024)
  • Anzu SPAC GP I LLC Filed SCHEDULE 13D on Envoy Medical, Inc., latest Dec 26, 2024
  • GLAZER CAPITAL, LLC Filed SC 13G/A on Envoy Medical, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Envoy Medical, Inc. White Bear Lake, Minnesota

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Envoy Medical, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$6.1M4 Dec 31, 2025$6.1M4 Dec 31, 2024+0.6%
Accumulated depreciation$5.1M4 Dec 31, 2025$4.8M4 Dec 31, 2024+5.8%
Property and equipment, net$1.0M4 Dec 31, 2025$1.3M4 Dec 31, 2024−18.8%

Real estate and locations

ItemLatestA year beforeChange
Area of land11,540 sq ft6 Dec 31, 2024

Inventory

ItemLatestA year beforeChange
Inventory, total$1.5M4 Dec 31, 2025$1.7M4 Dec 31, 2024−9.5%
Raw materials$1.3M4 Dec 31, 2025$1.4M4 Dec 31, 2024−8.9%
Work in process$88.0K4 Dec 31, 2025$203.0K4 Dec 31, 2024−56.7%
Finished goods$196.0K4 Dec 31, 2025$119.0K4 Dec 31, 2024+64.7%

Properties, in its own words

Our principal office is located at 4875 White Bear Parkway, White Bear Lake, Minnesota, where we lease approximately 13,500 square feet of office space. We lease this space under a lease that terminates on December 31, 2030. We believe that our existing facility is sufficient to meet our needs for the foreseeable future.

We also lease 1,100 square feet of office space in Ausbach, Germany pursuant to a lease that automatically renews each year for a successive one year period, unless we notify the landlord 6 months prior to the annual renewal. This lease renewed automatically on January 1, 2025 and again on January 1, 2026.

Item 2 of the 10-K filed Mar 23, 2026.3

Leadership

Who has led Envoy Medical, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Whitney Haring-Smith2021
  2. Brent T. Lucas2023–now

Chief financial officer

  1. Daniel J. Hirsch2022–2023
  2. David R. Wells2023
  3. Robert Potashnick2025–now
2025
Board members and other officers (17)

Former names

  • Anzu Special Acquisition Corp IJan 19, 2021 to Sep 29, 20232

Timeline

  1. Oct 7, 20268-K Other events30
  2. Aug 27, 20268-K Executive or director change31
  3. Aug 10, 20268-K Results of operations32
  4. Jun 30, 20268-K Ended a material agreement33
  5. Jun 25, 20268-K Executive or director change34
  6. May 22, 20268-K Listing notice or transfer35
  7. May 18, 20268-K Executive or director change; Shareholder vote36
  8. May 11, 20268-K Results of operations37
  9. Apr 21, 20268-K Executive or director change38
  10. Mar 31, 20268-K Change of auditor39
  11. Mar 27, 20268-K Results of operations40
  12. Feb 27, 20268-K Listing notice or transfer; Other events41
  13. Sep 29, 2023New chief executive Brent T. Lucas becomes CEO11
  14. Mar 1, 2021New chief executive Whitney Haring-Smith becomes CEO12

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.35) a share, on Nov 10, 2025.42

When it reported results

  1. Aug 10, 2026Reported quarterly or annual results32
  2. May 11, 2026Reported quarterly or annual results37
  3. Mar 27, 2026Reported quarterly or annual results40
  4. Nov 10, 2025Reported quarterly or annual results43
  5. Jul 31, 2025Reported quarterly or annual results44
  6. May 1, 2025Reported quarterly or annual results45
  7. Mar 31, 2025Reported quarterly or annual results46
  8. Nov 14, 2024Reported quarterly or annual results47

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

304 filings to the SEC since October 2021: 6 annual reports, 17 quarterly reports, 78 major events, 71 insider forms, 18 large holders, 114 other. The latest 20:

  1. Oct 7, 20268-K CURRENT REPORT EDGAR
  2. Sep 14, 2026SCHEDULE 13G/A EDGAR
  3. Sep 2, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  4. Aug 31, 2026DEF 14A PROXY STATEMENT EDGAR
  5. Aug 27, 20268-K CURRENT REPORT EDGAR
  6. Aug 26, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  7. Aug 19, 2026PRE 14A PROXY STATEMENT EDGAR
  8. Aug 10, 20268-K CURRENT REPORT EDGAR
  9. Aug 10, 202610-Q QUARTERLY REPORT EDGAR
  10. Jun 30, 20268-K CURRENT REPORT EDGAR
  11. Jun 25, 20268-K CURRENT REPORT EDGAR
  12. Jun 23, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  13. Jun 16, 2026EFFECT EDGAR
  14. Jun 12, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
  15. Jun 12, 2026S-8 REGISTRATION STATEMENT EDGAR
  16. Jun 4, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  17. May 22, 20268-K CURRENT REPORT EDGAR
  18. May 18, 20268-K CURRENT REPORT EDGAR
  19. May 15, 2026SCHEDULE 13G EDGAR
  20. May 14, 2026SCHEDULE 13G EDGAR

The 304 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 15 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 12, 2026TAYLOR GLEN A10% ownerBuy18,750,000$0.40$7.5MForm 4
Feb 12, 2026Patel Mona ChetanDirectorBuy312,500$0.40$125.0KForm 4
Feb 12, 2026Potashnick RobertCAO & VP of FinanceBuy212,500$0.40$85.0KForm 4
Feb 12, 2026Kantor SusanDirectorBuy96,150$0.40$38.5KForm 4
Feb 12, 2026BRYNELSEN CHARLESDirectorBuy1,000,000$0.40$400.0KForm 4
Feb 12, 2026Lucas Brent T.Chief Executive OfficerBuy62,500$0.40$25.0KForm 4
Jun 11, 2025Patel Mona ChetanDirectorBuy2,500$1.47$3.7KForm 4
Jun 6, 2025Patel Mona ChetanDirectorBuy10,000$1.46$14.6KForm 4
May 27, 2025BRYNELSEN CHARLESDirectorBuy35,000$1.65$57.8KForm 4
May 23, 2025BRYNELSEN CHARLESDirectorBuy13,000$1.64$21.3KForm 4
May 22, 2025BRYNELSEN CHARLESDirectorBuy2,000$1.68$3.4KForm 4
Nov 20, 2024Patel Mona ChetanDirectorBuy2,500$2.28$5.7KForm 4
Sep 11, 2024Patel Mona ChetanDirectorBuy4,000$3.33$13.3KForm 4
Sep 9, 2024Patel Mona ChetanDirectorBuy1,000$3.20$3.2KForm 4
Nov 21, 2023Lucas Brent T.Chief Executive OfficerBuy12,380$0.97$12.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 32. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC15,300,000$11.9M0.4%+7,650,000
Bleichroeder LP6,250,000$5.0M0.9%No change
Vanguard Capital Management LLC880,214$697.1K0.0%−1,458
DSG Capital Advisors, LLC625,000$474.2K0.1%No change
Geode Capital Management, LLC541,729$429.1K0.0%+19,905
Focus Partners Wealth425,310$336.8K0.0%+212,655
Vanguard Fiduciary Trust Co296,679$235.0K0.0%+1,958
UBS Group AG190,838$151.1K0.0%+120,379
Arcus Capital Partners, LLC187,573$148.6K0.1%No change
ExodusPoint Capital Management, LP182,354$144.4K0.0%New
Northern Trust Corp109,466$86.7K0.0%−1,584
Morgan Stanley90,921$72.0K0.0%+17,021
CIBC Bancorp USA Inc.77,887$61.7K0.0%No change
LPL Financial LLC48,401$38.3K0.0%+20,000
Jane Street Group, LLC31,223$24.7K0.0%New
Meteora Capital, LLC28,051$22.2K0.0%No change
State Street Corp23,872$18.9K0.0%No change
XTX Topco Ltd17,146$13.6K0.0%New
Afg Fiduciary Services Limited Partnership12,000$9.0K0.0%No change
BlueStem Wealth Partners, LLC10,454$8.3K0.0%No change
Spire Wealth Management10,025$7.9K0.0%New
Ballew Advisors, Inc10,121$7.6K0.0%No change
BlackRock, Inc.5,309$4.2K0.0%−42,205
Wolff Wiese Magana LLC4,000$3.2K0.0%New
Vanguard Global Advisers, LLC3,788$3.0K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Envoy Medical, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREnvoy Medical, Inc.1
  • CIK0001840877
  • Employer ID (EIN)86-13691233
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address4875 White Bear Parkway, White Bear Lake, MN 551101
  • Phone651-361-80001
  • Shares outstanding77,194,595 as of Aug 10, 20269
  • Public float$12.7M as of Dec 31, 20253
  • AuditorGRANT THORNTON LLP, Fort Lauderdale, Florida PCAOB ID 248; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJan 19, 20211
  • Filings326 in all: 8-K (80), 4 (57), 3 (20), 10-Q (17), 424B3 (17), CORRESP (14), DEFA14A (12), UPLOAD (11)1
    All 41 form types

    EFFECT (8), DEF 14A (7), S-1/A (7), 10-K (5), 425 (5), PRE 14A (5), S-4/A (5), 424B5 (4), S-1 (4), SC 13G (4), SCHEDULE 13G (4), SCHEDULE 13G/A (4), 424B4 (3), ARS (3), POS AM (3), SC 13G/A (3), 10-Q/A (2), 8-K/A (2), DRS (2), NT 10-Q (2), S-1MEF (2), S-8 (2), SCHEDULE 13D (2), 10-K/A (1), 25-NSE (1), 4/A (1), 8-A12B (1), CERT (1), DRSLTR (1), NT 10-K (1), S-3 (1), S-4 (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 23, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Aug 31, 2026
    Latest 8-K (8-K) Oct 7, 2026

Securities registered for trading

ClassSymbolExchange
Class A Common Stock, par value $0.0001 per shareCOCHThe Nasdaq Stock Market LLC
Redeemable Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per shareCOCHWThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 23, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Envoy Medical, Inc. names in Item 1A of its 10-K filed Mar 23, 2026: 39 risks under these headings, as written.3

  • Risks Relating to Our Class A Common Stock
  • The market price of our Class A Common Stock has been and may continue to be extremely volatile, which could cause purchasers of our securities to incur substantial losses.
  • Currently, our Class A Common Stock is listed on Nasdaq. However, limited liquidity in the market may limit the ability to sell shares of our Class A Common Stock at a favorable price.
  • The exercise of our outstanding Warrants would result in substantial increase in the number of shares eligible for future resale in the public market and result in dilution to our stockholders.
  • While we will pay dividends on shares of Series A Preferred Stock pursuant to the Certificate of Designation, we do not intend to pay dividends on shares of Class A Common Stock for the foreseeable future.
  • If analysts do not publish research about our business or if they publish inaccurate or unfavorable research, our stock price and trading volume could decline.
  • You may experience future dilution as a result of future equity offerings.
  • We may be subject to securities litigation, which is expensive and could divert management attention.
  • We are and may become involved in legal proceedings, and no assurance can be provided as to the outcome of these matters.
  • Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our Class A Common Stock from Nasdaq.
  • Risks Relating to Our Business and Operations
  • We are an early-stage company with a history of losses. We have not been profitable historically and may not be able to achieve profitability in the future.
The other 29 risks
  • We have generated limited revenue from product sales and may never be profitable.
  • If the Acclaim CI contains design or manufacturing defects, our business and financial results could be harmed.
  • We expect that we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations.
  • Raising additional capital would cause dilution to our existing stockholders and may adversely affect the rights of existing stockholders.
  • Failure of a key information technology system, process or site could have an adverse effect on our business.
  • Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.
  • We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and the value of our common stock.
  • Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
  • Clinical failure can occur at any stage of clinical development. Our clinical experience to date does not necessarily predict future results and may not have revealed certain potential limitations of the technology or potential complications from the Acclaim CI and may require further clinical validation. Any product version we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.
  • The successful commercialization of the Acclaim CI, if it receives FDA approval, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates could limit our ability to market those products and decrease our ability to generate revenue.
  • We operate in a very competitive business environment, and if we are unable to compete successfully against our existing or potential competitors, our business, financial condition and results of operations may be adversely affected.
  • We expect to derive most of our revenues from sales of the Acclaim CI. Our inability to successfully commercialize this product candidate or any subsequent decline in demand for this product candidate, could severely harm our ability to generate revenues.
  • If healthcare professionals do not recommend our product to their patients, the Acclaim CI may not achieve market acceptance and we may not become profitable.
  • We will be dependent upon contract manufacturing organizations and material suppliers, making us vulnerable to supply shortages and problems, increased costs and quality or compliance issues, any of which could harm our business.
  • Our business plan relies on certain assumptions about the market for our product; however, the size and expected growth of our addressable market has not been established with precision and may be smaller than we estimate, and even if the addressable market is as large as we have estimated, we may not be able to capture market share.
  • We will depend on third parties to manage our pre-clinical studies and clinical trials, perform related data collection and analysis, and to enroll patients for our clinical trials, and, as a result, we may face costs and delays that are beyond our control.
  • We have been and in the future may become a defendant in one or more stockholder derivative, class-action, and other litigation, and any such lawsuits may adversely affect our business, financial condition, results of operations and cash flows.
  • We are highly dependent on key members of our executive management team. Our inability to retain these individuals could impede our business plan and growth strategies, which could have a negative impact on our business and the value of your investment.
  • Certain of our directors and/or officers may have interests that are different from holders of our Class A Common Stock.
  • Risks Relating to Our Intellectual Property
  • If we are unable to obtain significant patent protection for our products, or if our patents and other intellectual property rights do not adequately protect our products, we may be unable to gain significant market share and be unable to operate our business profitably.
  • Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We may become a party to lawsuits or administrative proceedings involving patents or other intellectual property. If we were to lose any future intellectual property lawsuits, a court could require us to pay significant damages and/or prevent us from selling our products.
  • If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our competitive position may be harmed.
  • Patent terms may not be sufficient to effectively protect our products and business for an adequate period of time.
  • We may be unable to enforce our intellectual property rights throughout the world.
  • We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.
  • Risks Relating to Our Organization and Structure
  • Our Charter provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
  • As an “emerging growth company,” we cannot be certain if the reduced disclosure requirements applicable to “emerging growth companies” will make the Class A Common Stock less attractive to investors.
  • The requirements of being a public company may strain our resources and divert management’s attention.

Legal proceedings

From time to time, we may be involved in various claims and legal actions in the ordinary course of business. Except as described below, we are not currently involved in any material legal proceedings outside the ordinary course of our business.

On November 14, 2023, the Company, Whitney Haring-Smith (the former chief executive officer and a former director of the Company), Daniel Hirsch (the former chief financial officer of the Company), and Anzu SPAC GP I LLC were named as defendants in a complaint filed by Atlas Merchant Capital SPAC Fund I LP (“Atlas”) in the Delaware Court of Chancery. Atlas alleges that it was not allowed to redeem its shares of the Anzu class A common stock and that Defendants acted to prevent Atlas’s attempt to redeem its shares. Defendants assert that Atlas did not comply with the requirements for redeeming shares set forth in the Company’s organizational documents. Atlas asserts damages in the amount of approximately $9.4 million, pre- and post-judgment interest, costs, and reasonable attorneys’ fees. The Company has standard indemnification obligations to Dr. Haring-Smith and Mr. Hirsch. The Company believes that the lawsuit is meritless and has been defending this matter vigorously. The Company is unable to predict the outcome of this legal proceeding.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56